Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
JAMA · 2023 · 2,315 citations · Stephen Salloway
Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines.
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2021 · 1,135 citations · Linda Carpenter
Lecanemab: Appropriate Use Recommendations.
The journal of prevention of Alzheimer's disease · 2023 · 755 citations · Stephen Salloway
Donanemab in Early Alzheimer's Disease.
The New England journal of medicine · 2021 · 1,335 citations · Stephen Salloway
Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial.
JAMA · 2025 · 182 citations · Stephen Salloway
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.
The Lancet. Neurology · 2021 · 779 citations · Stephen Salloway
Donanemab: Appropriate use recommendations.
The journal of prevention of Alzheimer's disease · 2025 · 180 citations · Stephen Salloway
Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease.
Nature reviews. Neurology · 2024 · 276 citations · Stephen Salloway